Events

NeurIPS 2021 x LMLR Workshop w/ BenevolentAI Scientists

Join the BenevolentAI team at the NeurIPS 2021 LMLR workshop.

Neural Information Processing Systems (NeurIPS) is a prestigious peer reviewed conference that aims at publishing cutting edge research in artificial intelligence, machine learning and their related areas.

We look forward to returning to NeurIPS to present two posters at the LMRL workshop.

Poster 1: Contrastive VAE models to identify independent disease mechanisms in single-cell data


Identifying differences between sample groups such as patient cohorts or cell types provides insight into characteristics particular to a group of interest. Contrastive latent variable models can summarize signals in the data into a low-dimensional space and yield background and foreground specific latent variables. However, the sources of variation in the latent space can be entangled, and formulating VAE models that encourage independence on latents is an open area of research.

In this work, we focused on scRNA-seq data assumed to have underlying background variation shared among all the samples and additional foreground signals specific to some. Our task was to separate the signals into background and foreground-specific independent latents. We investigated several contrastive VAE models for scRNA-seq data and observed that combining them with Independent Component Analysis (ICA) leads to a good separation of independent background and foreground components, thus encouraging contrastiveness as well as independence. Further work on such models will allow us to better understand disease biology and lead to the discovery of novel drug targets and specific biomarkers.

Authors: Atanasiu Demian, Harry Rose, Sam Abujudeh & Meltem Gürel

Presented by: Atanasiu Demian - BenevolentAI Summer Intern

Atanasiu completed an MSci in Mathematics & Statistics at University of Bristol and is now in the third year of his PhD in Medical Sciences at University of Oxford. Atanasiu’s research focuses on Bayesian modelling of single cell data, in particular, applications of deep learning. Atanasiu is looking to apply this research to better understand the production of hematopoietic stem cells in embryos.

Poster 2: Benchmarking algorithms to identify clinically-relevant sub-populations of patients

A key focus of precision medicine initiatives is to move beyond the ‘one-size-fits-all’ treatment approach by identifying sub-populations of patients with different clinico-pathological manifestations of disease or response to standard-of-care treatments. Patients’ sub-populations can then be further characterized to identify underlying biological mechanisms driving the specific clinical phenotype, enabling personalised prioritization of therapeutics. 

In this work, we sought to benchmark the application of different combinations of feature transformations with patients clustering algorithms. We assessed performances by quantifying how well these algorithms recovered known clinically-relevant sub-populations and how stable the results are in both simulated and real-world patient-level transcriptomic datasets, including multiple oncological diseases. 

When benchmarking algorithms across multiple use-cases, we observed consistent performance patterns and identified methods with slightly better recovery of patients’ sub-populations. These results pave the way for identifying sub-populations of patients with mechanism-specific dysregulations (endotyping) by applying selected algorithms on features specifically associated with a pathway of interest rather than the whole feature space.

Authors: Manuela Salvucci, Meltem Gürel, Samer Abujudeh, Marika Catapano, Gregor Lueg, Matyas Korom, Manav Leslie, Peter McErlean, Francesca Mulas

Presented by: Manuela Salvucci

Manuela has joined BenevolentAI as a senior Bioinformatics Data Scientist in the PMPT Precision Medicine team. She studied biomedical engineering, completed a PhD in systems biology and continued working in computational biology during her PosDoc at The Royal College of Surgeons in Ireland. Manuela has focused her work in the last few years on omics data for translational applications in cancer.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022